Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

ing Group’s updated data set. Time to death specifically attributed to mammary adenocarcinoma was significantly decreased only in the lorcaserin high-dose group. In a second analysis which assumed deaths due to unspecified mammary tumor in rats with both fibroadenoma and adenocarcinoma were caused by adenocarcinoma, time to death was accelerated in the lorcaserin mid-dose group as well, although the incidence of mammary adenocarcinoma was not increased over controls in the mid-dose group.
  • A series of mechanistic studies that are intended to test whether there is a causal relationship between lorcaserin, prolactin and mammary tumor development in rats is ongoing. Arena expects to complete these studies in time to submit the complete response to the FDA around the end of the year.
  • Assigned the UK's Medicines and Healthcare products Regulatory Agency as marketing authorization application Rapporteur and Sweden's Medical Products Agency as Co-rapporteur. Arena also received approval from the Pediatric Development Committee for its pediatric investigation plan application, which defers all pediatric studies until after European Medicines Agency approval.

  • Other recent developments include:

  • Entered into an equity line of credit agreement with Azimuth Opportunity, L.P., or Azimuth, that provides that, upon the terms and subject to the conditions and limitations set forth in the agreement, Azimuth is committed to purchase up to $50 million worth of shares of Arena common stock over a 24-month term. Arena will determine, at its sole discretion, the timing and amount of any sales of its stock, subject to certain conditions.
  • Presented three posters of new data analyses from the lorcaserin Phase 3 clinical trial program at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society.
  • Announced that Robert E. Hoffman rejoined Arena as Vice President, Finance and Chief Financial Officer.

  • Sched
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
    3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
    4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
    5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
    6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
    7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
    8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
    9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
    10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
    11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... , July 25, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... June 30, 2014. "The second ... Semler," said Doug Murphy-Chutorian , M.D., chief ...
    (Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
    (Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
    Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
    (Date:7/27/2014)... 27, 2014 The constant expansion of ... in demand for enterprise video. Additional factors that have ... in areas such as corporate communication, learning and development, ... to all these factors the enterprise video market value ... to reach $35.57 billion in 2018 with a compound ...
    (Date:7/27/2014)... 27, 2014 This is a ... Chinese Dutasteride (CAS 164656-23-9) industry. The report firstly ... including its classification, application and manufacturing technology. The ... of Dutasteride (CAS 164656-23-9) listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
    (Date:7/27/2014)... 1-Butene is a colorless, combustible gas with ... can be manufactured either through the separation from crude ... Linear alpha olefin (alkene) 1-Butene is a versatile chemical ... important chemicals such as linear light density polyethylene (LLDP), ... 1-Butene market is extremely competitive. The market has several ...
    (Date:7/27/2014)... July 27, 2014 As Tylenol ... continue to move forward in federal court, Bernstein ... questioning one of the benefits purportedly associated with ... The research, which appears in the The Lancet, ... all of whom were given either acetaminophen or ...
    (Date:7/27/2014)... iFitDress.com, a well-known wedding dress manufacturer ... wedding gowns with sleeves . Furthermore, it has ... are now available with big discounts, from 20 to ... iFitDress.com is one of the big players in the ... new wedding gowns feature fine craftsmanship and charming looks. ...
    Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2
    ... are discriminated against.,// ,There are signs in the UK ... bashful about it either, according to sources from the country’s ... to convince them that they should lose weight. The country’s ... of the country’s children are overweight, while 13% are obese. ...
    ... Russia will hold a beauty contest in which only HIV ... difference will be held in Russia on 1 December 2005, ... positive girls will participate.// The contest has been named ‘Miss ... attitude of the public with regard to the scourge, and ...
    ... both variant forms of a gene called CYP2A6, which are ... addiction.// The protein product of these genes is believed to ... ,The two identified gene forms are found to decrease ... more specifically found to account for slow processing of nicotine ...
    ... elderly heart failure patients in United States have better ... advantage over time.// ,Their study findings appear in ... ,Heart failure is the most common cause of ... countries. ,The authors compared process of care and ...
    ... patients with liver cancer. A cloud of confusion however ... who harbors a liver tumor that cannot be removed ... available for this group of patients. ,Thanks ... now suggested a novel plan for combating these tumors ...
    ... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
    Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2
    ... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
    ... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
    ... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
    ... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
    Medicine Products: